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Background: A long-duration exploration class mission is fraught with numerous 
medical contingency plans.  Herein, we explore the challenges of symptomatic atrial 
fibrillation (AF) occurring during an exploration class mission.  The actions and 
resources required to ameliorate the situation, including the availability of appropriate 
pharmaceuticals, monitoring devices, treatment modalities, and communication 
protocols will be investigated.   
Challenges of Atrial Fibrillation during an Exploration Mission: Numerous etiologies 
are responsible for the initiation of AF.  On Earth, we have the time and medical 
resources to evaluate and determine the causative situation for most cases of AF and 
initiate therapy accordingly.  During a long-duration exploration class mission resources 
will be severely restricted.  How is one to determine if new onset AF is due to recent 
myocardial infarction, pulmonary embolism, fluid overload, thyrotoxicosis, cardiac 
structural abnormalities, or CO poisoning?  Which pharmaceutical therapy should be 
initiated and what potential side effects can be expected?  Should anti-coagulation 
therapy be initiated?  How would one monitor the therapeutic treatment of AF in 
microgravity?  What training would medical officers require, and which communication 
strategies should be developed to enable the best, safest therapeutic options for 
treatment of AF during a long-duration exploration class mission? 
Summary: These questions will be investigated with expert opinion on disease 
elucidation, efficient pharmacology, therapeutic monitoring, telecommunication 
strategies, and mission cost parameters with emphasis on atrial fibrillation being just one 
illustration of the tremendous challenges that face a long-duration exploration mission.  
The limited crew training time, medical hardware, and drugs manifested to deal with 
such an event predicate that aggressive primary and secondary prevention strategies be 
developed to protect a multibillion-dollar asset like the International Space Station or a 
mission to the Moon or Mars. 
Learning Objectives: The audience will become familiar with the risks and challenges 
inherent to developing a therapeutic strategy for the treatment of atrial fibrillation during 
a long-term exploration class mission.  
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